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In the last 15 years, orthopaedic practice has been revo-
lutionized by the amazing progresses made in the field of
biotechnologies, which led to the introduction of innova-
tive therapeutical approaches aimed at minimizing surgical
distress for patients and, at the same time, providing better
healing chances formanymusculoskeletal diseases [1]. Beside
the great enthusiasm for novel strategies represented by the
use of biomaterials and biologic agents, such as autologous
growth factors [2] and stem cells [3], there has been also an
increasing awareness on the necessity of better understanding
the mechanisms of pathology, improving our diagnostic
skills, and identifying positive and negative prognostic factors
[4]. In fact, not only is the “therapeutic success” based on
the treatment itself, but it is the result of a more complex
interaction of factors: an early diagnosis, a proper timing
for starting the treatment, and the specific patient features
which could determine either a satisfactory or poor outcome.
This multifactorial approach is usually regarded as “patient
profiling” and represents the pinnacle of the “personalized
medicine” which is the ultimate goal of current research in
all medical specialties [5]: providing a treatment “tailored”
to the specific needs of the patients in order to maximize
the benefit and reduce potential side effects. Therefore, the
focus of clinicians has shifted from the pathology as a
stand-alone entity to the concept of “pathology within a
specific patient”: based on this conception, it is not only
the disease that changes the “homeostasis” of the patient,
but the patient himself can influence the course of the
pathology in a favourable or negative manner, depending on
his/her particular features [6, 7]. The challenge is always to
understand how to take advantage of the “pros” and how to
get rid of the “cons.”
This was the idea that led us to propose the present
special issue, whose title reflects the curiosity of all the guest
editors towards the potential ways to enhance the outcomes
of musculoskeletal surgery. The title is very broad, and we
expected contributions coming from very different areas,
ranging from basic traumatology to elective surgery and
also preclinical experiments. This was a conscious choice,
since we believe that sharing ideas from a wide range of
different clinical scenarios could be a winning method to
provide fruitful stimuli to the readers, avoiding excessive
subspecialization: sometimes to find solutions you have to
raise your eyes from the microscope and take a wider look
around you. We believe that innovative strategies in one par-
ticular field might perhaps be applied in completely different
situations, and therefore it would have been interesting to
include in the same special issue perspectives coming from
basic researchers, traumatologists, spine surgeons, sports
medicine surgeons, and so on. We are truly glad to have
received such a great interest, which is testified by a total of
15 papers accepted. Looking at the topics proposed in the
whole issue, four main areas can be identified: (1) biomarkers
and molecular pathways (for early diagnosis or as potential
therapeutic target); (2) computer aided surgery and patient-
specific implants; (3) biomaterials and biologic agents for
tissue regeneration; (4) evaluation of prognostic factors after
surgery. All the major fields related to the “personalization”
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of the treatment have been covered, with very interesting
contributions. Regarding biomarkers and molecular path-
ways, four papers have been included in the issue: one
investigated the role of serumbiomarkers in predicting heart-
related complications following hip fracture, one dealt with
synovial procalcitonin for the detection of periprosthetic
joint infection, one focused on ACL reconstructive surgery,
and, lastly, there was an interesting review on the role
of Wnt-pathway in the pathogenesis of OA. Looking at
computer aided surgery and patients’ specific implants, we
have papers dealing with innovative frames for pelvic fracture
stabilization and 3D-printed PEEK hardware. In the field
of biomaterials and regenerative medicine we included an
animal trial onAchilles tendon collagen scaffold and a clinical
trial investigating the potential of PRP in stimulating healing
of partial ACL rupture. Considering papers on “prognostic
factors,” we included onemulticentric trial presenting a score
to predict tibial fracture healing time, one systematic review
on radial head fractures, one retrospective trial investigating
the failure predictors in pediatric forearm fractures, and one
pilot study which revealed particular histological features of
the articular capsule of patients affected by glenohumeral
instability.
Perhaps some readers will be bewildered by the variability
of the topics included, but we believe this is actually the
strength of our issue, which offered a panoramic overview on
the many different innovative approaches to the treatment of
disparate musculoskeletal conditions. Therefore, it should be
considered a starting point for future, more focused insights
on specific pathologies, in the attempt of strengthening the
conviction that the outcomes of innovative treatments are
strictly related to the timing of diagnosis and the patients’
intrinsic features. The mere “technological” improvement
will not provide better results if not accompanied by the
understanding of the disease mechanisms and the factors
playing a crucial role in its progress.
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